AbbVie has announced a $1.4 billion investment to develop a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, representing the company’s largest-ever capital investment in a single campus since its inception. Located near Research Triangle Park, the facility will serve as AbbVie’s US centre of excellence for small volume parenteral (SVP) manufacturing and will integrate advanced manufacturing and laboratory technologies with artificial intelligence to support the production of medicines across the company’s immunology, neuroscience and oncology portfolios. Construction is scheduled to begin in 2026, with campus completion expected by the end of 2028. The Durham campus is AbbVie’s first major investment in North Carolina and was selected for the depth of the region’s skilled life sciences workforce and the site’s capacity to support long-term future expansion. The first phase of construction will deliver SVP drug product manufacturing facilities, next-generation laboratories, a warehouse, administrative offices and employee wellness facilities. Small volume parenterals are sterile injectable pharmaceutical products with volumes typically below 100 mL, encompassing vials, prefilled cartridges and prefilled syringes used for injectable or infused medicines. Over the next four years, AbbVie plans to hire 734 permanent employees, including engineers, scientists, manufacturing operators and laboratory technicians, while the campus development phase is expected to generate more than 2,000 construction jobs.
The Durham announcement lands at a moment when North Carolina’s Research Triangle region has firmly consolidated its position as one of the most competitive pharmaceutical and life sciences manufacturing destinations in the United States. The region’s combination of Tier 1 research universities, an established biotech and pharma supply chain, and a workforce with manufacturing-grade life sciences credentials makes it a natural draw for companies seeking to build capital-intensive facilities at scale. AbbVie’s choice of Durham also needs to be read in the context of the broader pharmaceutical manufacturing reshoring dynamic that is reshaping capital allocation decisions across the industry. With US$100 billion committed to domestic R&D and capital investments over the next decade, AbbVie is positioning itself alongside Eli Lilly, Pfizer and other major pharmaceutical companies that have each announced large-scale US manufacturing expansions in recent years, partly in response to supply chain vulnerability concerns exposed during the post-pandemic period and partly in anticipation of regulatory and policy pressure around domestic pharmaceutical production.
This expansion trend is already visible in AbbVie’s wider U.S. footprint, including the recent groundbreaking of its USD 195 million API manufacturing facility in North Chicago, which further signals the company’s commitment to strengthening domestic production capacity across both drug substance and advanced delivery formats. Durham’s proximity to Research Triangle Park, the largest research park in the United States by employment, gives AbbVie a recruitment and collaboration advantage that is difficult to replicate elsewhere, particularly for a facility requiring deep integration of AI-driven manufacturing systems with laboratory and clinical supply chain functions. The SVP focus of this campus is strategically significant, because prefilled syringes and injectable biologics now represent some of the highest-growth formats in pharmaceutical delivery globally, and establishing a domestic centre of excellence in this area positions AbbVie to serve both current immunology blockbusters and next-generation pipeline programmes from a single, purpose-built US location.
Campus Programme, Manufacturing Scope and Workforce Plan
- Total investment: $1.4 billion
- Campus area: 185 acres, Durham, North Carolina
- Location: near Research Triangle Park, North Carolina
- Phase 1 construction includes: SVP drug product manufacturing facilities, next-generation laboratories, warehouse, administrative offices and employee wellness facilities
- Manufacturing focus: small volume parenterals (SVP), covering vials, prefilled cartridges and prefilled syringes for injectable and infused medicines
- Technology integration: advanced manufacturing systems combined with artificial intelligence
- Therapeutic areas supported: immunology, neuroscience and oncology
- Permanent jobs to be created (over four years): 734 roles including engineers, scientists, manufacturing operators and laboratory technicians
- Construction jobs during campus development: more than 2,000
- Campus designation: AbbVie’s US centre of excellence for SVP manufacturing
- Site structured to accommodate future expansion phases
Project Fact Sheet
- Project Name: AbbVie Durham Campus
- Developer/Owner: AbbVie Inc. (NYSE: ABBV)
- Location: Durham, North Carolina, near Research Triangle Park
- Project Type: Pharmaceutical manufacturing campus (greenfield)
- Total Investment: $1.4 billion
- Campus Area: 185 acres
- Manufacturing Category: Small Volume Parenteral (SVP) drug product manufacturing and next-generation laboratory operations
- Therapeutic Focus: Immunology, neuroscience and oncology
- AI Integration: Advanced AI-enabled manufacturing and laboratory technologies embedded in campus design
- Construction Start: 2026
- Completion Target: end of 2028
- Permanent Jobs Created: 734 (engineers, scientists, manufacturing operators, laboratory technicians)
- Construction Jobs Supported: more than 2,000
- Significance: AbbVie’s largest-ever capital investment in a single campus since company inception; first major investment in North Carolina
- Programme Context: Part of AbbVie’s $100 billion commitment to US R&D and capital investments including manufacturing over the next decade
- Recent US Manufacturing Commitments (past 12 months): more than $2.2 billion across North Carolina, Illinois, Arizona and Massachusetts; more than 1,300 jobs committed
- US Workforce: approximately 29,000 employees nationwide; more than 6,000 at US manufacturing campuses
- Global Manufacturing Presence: operations across all 50 US states and Puerto Rico
Project Team
- Owner/Developer: AbbVie Inc. — a global biopharmaceutical company headquartered in North Chicago, Illinois, focused on immunology, neuroscience, oncology and aesthetics; listed on the New York Stock Exchange (ABBV)
- Chairman and Chief Executive Officer, AbbVie: Robert A. Michael — announced the Durham campus investment and articulated the strategic rationale for expanding the company’s manufacturing footprint into the Research Triangle region
- State Government: Governor Josh Stein, State of North Carolina — welcomed the AbbVie investment as confirmation of North Carolina’s standing as a premier biopharmaceutical business destination
- Media Contact: Gabby Tarbert, AbbVie Corporate Communications — (224) 244-0111
- Investor Relations Contact: Liz Shea, AbbVie Investor Relations — (847) 935-2211
- Programme Context Partners: Research Triangle Park (proximity); North Carolina’s life sciences industry ecosystem including established biotech, pharmaceutical supply chain and Tier 1 university research infrastructure
